ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced that the company has appointed Regina E. Herzlinger to the company's Board of Directors, effective immediately. Dr. Herzlinger is a Professor at the Harvard Business School and is well known for her expertise in healthcare industry business and accounting practices. In conjunction with Dr. Herzlinger's appointment, Peter Svennilson will step down from the ChemoCentryx Board. The total number of Board members remains the same.
